Imatinib an Effective Front-line Therapy for Patients With Pediatric CML
Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.
Diagnosis & Disease Information
Lasting Outcomes for Imatinib in Chronic Myeloid Leukemia
The efficacy of imatinib for CML treatment persisted over time and long-term administration was not associated with unacceptable cumulative effects.
SWOG Study Shows Robust, Longer Survival With Imatinib Therapy for GIST
A phase 3 analysis of SWOG Intergroup Trial S0033 reveals that imatinib significantly extends survival in patients with GIST.
Safety of combining imatinib and radiotherapy
Is combination therapy of imatinib (Gleevec) and radiotherapy safe?
Adjuvant imatinib promising for failure-free survival in GIST
Adjuvant imatinib impacts short-term free from relapse in patients with localized, surgically resected, high/intermediate-risk gastrointestinal stromal tumors (GIST), according to interim results of an intergroup trial.
DNA-repair problems destroy hardy leukemia cells
Leukemia stem cells that overcome drug therapy can be thwarted when deprived of RAD52, a protein key to DNA repair of these cancer cells.
Oral therapy: Managing side effects can aid adherence
Diligent patient education that addresses adherence and persistence issues can optimize outcomes in patients with gastrointestinal stromal tumors.
Regorafenib prolongs survival in face of GI cancers
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Investigational drug is active against the most resistant types of chronic myeloid leukemia
A previously invincible mutation in chronic myeloid leukemia has been thwarted by the investigational drug, ponatinib, in a phase I clinical trial.
Targeted drug overcomes resistance in patients with rare sarcoma
Regorafenib, a new, targeted, oral drug, demonstrated the ability to control metastatic GIST, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies.
- Loading...
Loading...
Loading... 
Loading...